Novartis Ag (NVS) Minority Interest (2009 - 2026)
Novartis Ag (NVS) posted Minority Interest of $415.0 million for Q1 2026, down 0.95% sequentially from $419.0 million in Q4 2025, and up 400.0% YoY from $83.0 million in Q1 2025.
Novartis Ag (NVS) Minority Interest (2009 - 2026) Analysis & Trends
Novartis Ag has reported Minority Interest for 18 years, with the latest figure at $415.0 million in Q1 2026.
- Quarterly Minority Interest rose 400.0% year-over-year to $415.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $415.0 million (up 400.0% YoY) and the FY2025 annual result came in at $419.0 million, up 423.75% from the prior year.
- Minority Interest retreated to $415.0 million in Q1 2026 per NVS's latest filing, from $419.0 million in the prior quarter.
- Over five years, Minority Interest peaked at $422.0 million in Q3 2025 and troughed at $69.0 million in Q2 2025.
- A 5-year average of $152.8 million and a median of $83.0 million in 2023 frame the typical range for Minority Interest.
- The sharpest annual moves came in 2022 and 2025: Minority Interest surged 468.18% in 2022, then slumped 59.17% in 2025.
- Over 5 years, Minority Interest stood at $81.0 million in 2022, then grew by 2.47% to $83.0 million in 2023, then dropped by 3.61% to $80.0 million in 2024, then soared by 423.75% to $419.0 million in 2025, then slipped by 0.95% to $415.0 million in 2026.
- According to Business Quant data, Minority Interest over the past three periods registered $415.0 million, $419.0 million, and $422.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 415.00 Mn |
| Dec 31, 2025 | 419.00 Mn |
| Sep 30, 2025 | 422.00 Mn |
| Jun 30, 2025 | 69.00 Mn |
| Mar 31, 2025 | 83.00 Mn |
| Dec 31, 2024 | 80.00 Mn |
| Sep 30, 2024 | 124.00 Mn |
| Jun 30, 2024 | 169.00 Mn |
| Mar 31, 2024 | 81.00 Mn |
| Dec 31, 2023 | 83.00 Mn |
| Sep 30, 2023 | 81.00 Mn |
| Jun 30, 2023 | 84.00 Mn |
| Mar 31, 2023 | 83.00 Mn |
| Dec 31, 2022 | 81.00 Mn |
| Sep 30, 2022 | 78.00 Mn |
| Jun 30, 2022 | 81.00 Mn |
| Mar 31, 2022 | 164.00 Mn |
| Dec 31, 2021 | 167.00 Mn |
| Sep 30, 2021 | 166.00 Mn |
| Jun 30, 2021 | -22.00 Mn |